Inhibikase Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Inhibikase Therapeutics

15/05/2023 22:02

* Inhibikase Therapeutics Inc  IKT.OQ  reported a quarterly
adjusted loss of 16 cents​​ per share for the quarter ended in
March. The mean expectation of two analysts for the quarter was
for a loss of 14 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Inhibikase Therapeutics Inc's reported EPS for the quarter
was a
loss of 16 cents​.
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Inhibikase Therapeutics Inc shares had fallen by 6.8% this
quarter and gained 22.5% so far this year.
    * The company reported a quarterly loss of $4.42 million.
    * Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is $5.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 09:02 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.14          -0.16          Missed
 Dec. 31 2022      -0.19          -0.18          Beat
 Sep. 30 2022      -0.18          -0.18          Met
 Jun. 30 2022      -0.19          -0.18          Beat